Titan Medical Inc

Titan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.

Quantum International Corp. operates as an emerging robotics innovation company. It identifies and develops innovative products in the robotics, consumer electronics and lifestyle enhancement products. The company was founded on September 25, 2001 and is headquartered in Centennial, CO.

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company plans to issue its first quarter financial results prior to market opening Monday, May 17, 2021 and management will host an investor audio webcast at 4:30 p.m. ET to discuss financial results and business highlights. Speakers will include David J. Mc

Titan Medical to Report First Quarter 2021 Financial Results May 17, 2021

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Kristen Galfetti, MBA, as its Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President Finance. Ms. Galfetti will be located in Boston and Mr. Huang will be located in Toronto. "It is a pleasure to w

Titan Medical Expands Senior Leadership Team

The stock price of Titan Medical (NASDAQ: TMDI) increased by over 15% pre-market. This is why it happened.

Titan Medical Stock Price Increased Over 15% Pre-Market: Why It Happened

TORONTO--(BUSINESS WIRE)--Titan Medical to Present at Bloom Burton & Co. Healthcare Investor Conference

Titan Medical to Present at Bloom Burton & Co. Healthcare Investor Conference

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that, David McNally, President, CEO and Chairman and Monique Delorme, CFO of Titan Medical, will participate in two upcoming virtual investor conferences. On March 16, 2021, Titan Medical will lead a day of one-on-one meetings with investors at the 33rd Annual

Titan Medical to Participate in Upcoming Investor Conferences

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced a corporate update in conjunction with its presentation at the H.C. Wainwright Global Life Sciences Conference. David McNally, President, CEO and Chairman of Titan Medical, will provide an overview of the Company and its Enos™ robotic single access surgical sys

Titan Medical Issues Corporate Update

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President, CEO and Chairman of Titan Medical, will present an overview of the Company and its Enos™ robotic single access surgical system at the H.C. Wainwright virtual Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 a.m. E

Titan Medical to Present at H.C. Wainwright Global Life Sciences Conference

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 8,335,000 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of US $20,004,000 (the “Offering”). Bloom Burton Securities Inc. acted as underwriter for the Offering and exercised it

Titan Medical Announces Closing of US $23M Bought Deal Offering Including Full Exercise of Over-Allotment Option

Titan Medical Inc. (TMDI) CEO David McNally on Q4 2020 Results - Earnings Call Transcript

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the release of its annual financial results for the years ended December 31, 2020 and 2019. During the year ended December 31, 2020, the Company generated revenue of $20.0 million, resulting from development and license agreements with Medtronic plc, and raised

Titan Medical Reports Year-End 2020 Financial Results

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has filed and been receipted for a final short form prospectus with applicable securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 8,335,000 units of the Company (“Units”) on a “bought dea

Titan Medical Announces Filing of Final Short Form Prospectus

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company plans to issue its fourth quarter and year-end financial results prior to market opening Monday, February 22, 2021 and management will host an investor audio webcast at 4:30 pm ET to discuss financial results and business highlights. Speakers will in

Titan Medical to Report Year-End 2020 Financial Results and Host Webcast on February 22, 2021

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has filed a preliminary short form prospectus with applicable securities regulators in Ontario, British Columbia and Alberta in connection with its previously announced offering of 8,335,000 units of the Company (“Units”) on a “bought deal” basis, at a

Titan Medical Announces Filing of Preliminary Short Form Prospectus

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the “Underwriter”) to increase the amount of its previously announced “bought deal” offering. The Underwriter has now agreed to purchase, on a “bought deal” basis, 8,335,000 units of the Company (the “

Titan Medical Announces Upsize to Previously Announced Bought Deal Offering

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the “Underwriter”) pursuant to which the Underwriter has agreed to purchase, on a “bought deal” basis, 6,250,000 units of the Company (the “Units”) at a price of $2.40 per Unit (the “Offering Price”) f

Titan Medical Announces Us $15 Million Bought Deal Offering

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it closed its previously announced offering of 6,451,613 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of approximately US $10,000,000.00 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) acted as underwri

Titan Medical Announces Closing of US $11.5M Bought Deal Offering Including Full Exercise of Over-Allotment Option

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the “Underwriter”) pursuant to which the Underwriter has agreed to purchase, on a “bought deal” basis, 6,451,613 units of the Company (the “Units”) at a price of US$1.55 per Unit (the “Offering Price

Titan Medical Announces US$10 Million Bought Deal Offering

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company has received a written response from the U.S. Food & Drug Administration (“FDA”) to its Request for Information in accordance with Section 513(g) of the U.S. Federal Food, Drug and Cosmetic Act (“FD&C Act”), regarding the regulatory requireme

Titan Medical Provides Regulatory Update

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that on December 24, 2020, the Company received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has cured the bid price deficiency and has regained full compliance with all applicable criteria for continued listing and trading on The

Titan Medical Reports Full Compliance with Nasdaq Listing Criteria

Anchiano Therapeutics Ltd - ADR

cbdMD Inc

Zhongchao

As of Dec. 10, the GuruFocus All-in-One Screener, a Premium feature, found that the following health care companies have low price-earnings ratios and are owned by gurus. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

6 Health Care Stocks Trading With Low Price-Earnings Ratios

Titan Medical will be speaking at the Benzinga Global Small Cap Conference taking place on December 8-9, 2020. The use of multi-port robotic surgical systems is becoming more widely adopted in urology, gynecology, and general surgery.

Titan Medical: Driving Toward Improved Patient Outcomes Through Robotic Single Access Surgery

Is Titan Medical Inc. (NASDAQ:TMDI) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.

Do Hedge Funds Love Titan Medical Inc. (TMDI)?

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces financial results for the three and nine months ended September 30, 2020, highlighted by the Company's improved cash position, which, as of September 30, 2020, reflects a positive difference of approximately $24 million compared to its cash position at December 31, 2

Titan Medical Reports Third Quarter Financial Results

Medtronic

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) (NYSE: MDT), and is due to receive a U.S. $10 million payment. The development and license agreement provides for the development of

Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of robotic surgical technologies, announced today the launch of a new name and brand identity for its robotic surgical system under development, the Enos™ robotic single access surgical system. During the coming weeks, the Company will gradually transition to the new Enos brand identity, including on its website and in presentations and

News for Titan Medical Inc Stock (TMDI)